GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » DARA Biosciences Inc (NAS:DARA) » Definitions » Preferred Stock

DARA Biosciences (DARA Biosciences) Preferred Stock : $0.00 Mil (As of Sep. 2015)


View and export this data going back to . Start your Free Trial

What is DARA Biosciences Preferred Stock?

Preferred stock is a special equity security that has properties of both equity and debt. DARA Biosciences's preferred stock for the quarter that ended in Sep. 2015 was $0.00 Mil.

The market value of preferred stock needs to be added to the market value of common stocks in the calculation of Enterprise Value. DARA Biosciences's Enterprise Value for the quarter that ended in Sep. 2015 was $12.35 Mil.

In the calculation of book value, the par value of preferred stocks needs to subtracted from total equity. DARA Biosciences's Book Value per Share for the quarter that ended in Sep. 2015 was $0.31.

Dividends paid to preferred stocks need to be subtracted from net income in the calculation of Earnings per Share (Diluted). DARA Biosciences's Earnings per Share (Diluted) for the three months ended in Sep. 2015 was $-0.14.


DARA Biosciences Preferred Stock Historical Data

The historical data trend for DARA Biosciences's Preferred Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DARA Biosciences Preferred Stock Chart

DARA Biosciences Annual Data
Trend Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14
Preferred Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

DARA Biosciences Quarterly Data
Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15
Preferred Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

DARA Biosciences Preferred Stock Calculation

Preferred Stock is a special equity security that has properties of both equity and debt. It is generally considered a hybrid instrument. Preferred stock is senior to common stock, but is subordinate to bonds in terms of claim or rights to their share of the assets of the company.

Preferred stock has priority over common stock in the payment of dividends and any payments received when a company liquidates.

Preferred stock comes in many forms. It can be:


Convertible or Non-Convertible
Cumulative or Non-Cumulative
Voting or Non-Voting
Callable or Non-Callable
Maturity Date or No Maturity Date

A preferred stock without a maturity date is called a perpetual preferred stock. These are relatively rare. A good example of perpetual preferred stock is the many series of Public Storage (PSA) preferred shares that trade on the New York Stock Exchange.

Before investing in preferred stock, it is important to know which of the above groups the stock belongs to. Is it convertible or non-convertible? Are dividends cumulative or non-cumulative?

It is also critical that an investor knows what bonds the company has in front of the preferred stock. Bondholders get paid first. So the decision to buy a preferred stock can be similar to the decision to buy a bond. But, remember, the preferred stock of a company with bonds is junior to those bonds.

Unless a preferred stock is convertible, the upside in a preferred stock investment is more limited than in a common stock investment. If a company doubles its earnings, it is usually under no more obligation to double the dividends paid to preferred shareholders than it is to double the interest paid to its bankers and bondholders.So preferred stock is very different from common stock.


DARA Biosciences  (NAS:DARA) Preferred Stock Explanation

When a company needs capital but does not wish to issue debt, they may sell preferred stocks to investors.

For instance, during the financial crisis of 2008, Goldman Sachs (GS) issued a combination of preferred stock and common stock options for $5 billion of capital to Warren Buffett’s Berkshire Hathaway (BRK.A)(BRK.B). In this deal, Berkshire Hathaway paid $5 billion for 10% cumulative perpetual preferred stock and warrants to buy 43.5 million shares of Goldman Sachs at $115 a share. Goldman Sachs bought back the preferred in 2010. Guess how much money Warren Buffett made in this deal in two years? Read How Much Did Warren Buffett’s Berkshire Hathaway (BRK.B) Make on Its Goldman Sachs (GS) Preferred Stock?

1. The market value of Preferred Stocks needs to be added to the market value of common stocks in the calculation of enterprise value.

DARA Biosciences's Enterprise Value for the quarter that ended in Sep. 2015 is calculated as

2. In the calculation of Book Value, the par value of Preferred Stocks needs to subtracted from total equity.

DARA Biosciences's Book Value per Share for the quarter that ended in Sep. 2015 is calculated as

3. Dividends paid to Preferred Stocks need to be subtracted from net income in the calculation of earnings per share.

DARA Biosciences's Earnings per Share (Diluted) (EPS) for the three months ended in Sep. 2015 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


DARA Biosciences Preferred Stock Related Terms

Thank you for viewing the detailed overview of DARA Biosciences's Preferred Stock provided by GuruFocus.com. Please click on the following links to see related term pages.


DARA Biosciences (DARA Biosciences) Business Description

Traded in Other Exchanges
N/A
Address
DARA Biosciences Inc was incorporated on June 22, 2002. It is a specialty pharmaceutical company focused on the development and commercialization of oncology treatment and supportive care pharmaceutical products. Through its acquisition of Oncogenerix, Inc., which occurred on January 17, 2012, the Company acquired exclusive U.S. marketing rights to its first commercial proprietary product, Soltamox (oral liquid tamoxifen). The Company's main focus is on the development and commercialization of oncology treatment and supportive care pharmaceutical products: Soltamox, Gemcitabine and other generic sterile injectable cytotoxic products, and Cancer support therapeutics. Soltamox (oral liquid tamoxifen), its first proprietary, FDA approved product, is a drug primarily used to treat breast cancer. Soltamox has been approved by the U.S. Food and Drug Administration ('FDA') for the treatment of breast cancer. Soltamox will be the only liquid formulation of tamoxifen available for sale in the United States. Soltamox is used mainly for the chronic treatment of breast cancer or for cancer prevention in certain susceptible breast cancer subgroups. The Company is also focusing on the development and commercialization of generic sterile injectable cytotoxic products. The Company's agreement with Uman Pharma Inc. pursuant to which it received an exclusive license to import, sell, market and distribute Uman's gemcitabine lyophilized powder product in 200mg and 1g dosage sizes in the U.S. Gemcitabine went off patent in 2011 in the U.S. and is prescribed as first-line therapy for ovarian, breast, lung and pancreatic cancers. Currently, the Company has two main drug candidates advancing through clinical development with cleared Investigational New Drug applications from the FDA: KRN5500, a novel, non-narcotic/non-opioid for the treatment of neuropathic pain in patients with cancer; and DB959, a first-in-class drug candidate for the treatment of type 2 diabetes and dyslipidemia. The Company mainly competes with other pharmaceutical companies, biotechnology companies and other research and academic institutions. The Company's advertising, marketing and distribution of pharmaceutical products in the United States is subject to the regulation of United States Food, Drug and Cosmetic Act.
Executives
David Drutz director, officer: Executive Chairman and CMO 8601 SIX FORKS ROAD, SUITE 160, RALEIGH NC 27615
David L. Tousley officer: CFO 14610 PAWNEE LANE, LEAWOOD KS 66224
Gail Lieberman director 175 EAST 79TH STREET, APT. 4D, NEW YORK NY 10075
Paul John Richardson director 17 COUNTRY OAKS ROAD, LEBANON NJ 08833
Steve Gorlin director 150 GULF SHORE DRIVE, UNIT 601, DESTIN FL 32541
Ann A Rosar officer: Vice President Finance C/O 801 CAPITOLA DRIVE, DURHAM NC 27713
John C Thomas director 8601 SIX FORKS ROAD, SUITE 160, RALEIGH NC 27615
Geert Cauwenbergh director 1 STULTS DRIVE, PLAINSBORO NJ 08536
Kurt M Eichler director C/O SPRING BANK PHARMACEUTICALS, INC., STE S-7, MILFORD MA 01757
Hamilton Jordan director
Stuart C Mcwhorter director 113 SEABOARD LANE, FRANKLIN TN 37067
Timothy J Barberich director 40 ELM ST, CONCORD MA 01752
Michael P Duffy officer: SVP, GC and Secretary C/O POINT THERAPEUTICS INC, 125 SUMMER STREET SUITE 1840, BOSTON MA 02110
Richard J Benjamin director 15 WHITE PINE ROAD, NEWTON MA 02464
Larry G Pickering director 26130 MANDEVILLA DRIVE, BONITA SPRINGS FL 34134

DARA Biosciences (DARA Biosciences) Headlines